Pharmaceuticals

Organon

Organon released FY2026 Q1 earnings on April 30 Pre-Market (EST), actual revenue USD 1.46 B (forecast USD 1.488 B), actual EPS USD 0.55

Organon Reports 2026 Q1 Earnings with Net Income Decline

Organon to Release FY2026 Q1 Earnings on May 7 Pre-Market EST, Forecast Revenue USD 1.488 B

Sunny Pharmaceutical Industrial Agrees to Acquire Organon

EC Approves Henlius and Organon's POHERDY®

Organon & Co to pay $120 million termination fee to Sun Pharmaceutical Holdings USA

Sun Pharmaceutical to acquire Organon for $11.75 billion in cash to expand international footprint

Sun Pharma Agrees to Acquire Organon for $14 per Share

Organon Shares Surge 25.47% as Sun Pharma Plans $13 Billion Acquisition

Sun Pharma Makes a $12 Billion Binding Offer to Acquire Organon

Organon Reports FY2025 Earnings: Sales Down, Jada Exit, Tofidence Acquisition

Organon released FY2025 earnings on February 12 Pre-Market (EST), actual revenue USD 6.216 B (forecast USD 6.224 B), actual EPS USD 0.72 (forecast USD 1.92)

Organon released FY2025 Q4 earnings on February 12 Pre-Market (EST), actual revenue USD 1.507 B (forecast USD 1.515 B), actual EPS USD -0.79

Organon to Release FY2025 Q4 Earnings on February 12, Pre-Market EST; Forecast Revenue USD 1.519 B

Sun Pharma Considers $10 Billion Acquisition of Organon

Barclays Upgrades Organon & Co. Rating to 'Strong Sell'

Organon & Co. to Attend Piper Sandler Healthcare Conference

FDA Approves Organon and Fosun Henlius' POHERDY as First Perjeta Biosimilar in the US

Organon & Co's Executive Chair Carrie Smith Cox Acquires Shares

U.S. Bank Securities and Piper Sandler Maintain Sell Ratings for Organon

InMed Pharmaceuticals

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

Amesite

CN Energy

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

NextNRG

Meiwu Tech

Generation Income Properties

MetaVia

OceanPal

Organon & Co. (NYSE:OGN) has received a consensus rating of 'Reduce' from seven research firms, with three analysts recommending a sell and four a hold. The average 12-month price target is $11.40. Recent changes include Piper Sandler upgrading to 'neutral' with a price target of $14.00, while Zacks raised from 'strong sell' to 'hold'. Insider Lynette Holzbaur purchased 26,448 shares at $13.35 each. The stock opened at $13.40, with a market cap of $3.52 billion.

Market Beat

iShares US Pharma

Invesco Biotechnology & Genome ETF

First Trust NYSE Arca Biotech Index Fd

Invesco Nasdaq Biotechnology ETF

VanEck Biotech ETF

iShares Biotechnology ETF

VG Health

ALPS Medical Breakthrough

SPDR S&P Biotech

Proshares Ultra Nasdaq Biotech

Merck

Piper Sandler Cos

BNP Paribas

Barclays

Lululemon

S&P 500

ROYAL BANK OF CANADA

Goldman Sachs

UBS Group AG

GS Hldg R

Organon & Co. (NYSE:OGN) Receives Average Rating of "Reduce" from Brokerages

Organon to Present New Research on Access and Value at ISPOR 2026 | OGN Stock News

StockTitan

Ark Genomic Revolution ETF

Direxion S&P Biotech Bull 3X

Organon to Present New Research on Access and Value at ISPOR 2026 | OGN Stock News

XOMA

Halper Sadeh LLC is investigating XOMA, Organon & Co., and Veris Residential for potential violations of federal securities laws and breaches of fiduciary duties. The firm is concerned that insiders may benefit financially at the expense of ordinary shareholders in proposed transactions. Shareholders are encouraged to contact the firm to discuss their rights and options at no cost. The investigations focus on XOMA's sale for $39.00 per share, Organon's sale for $14.00 per share, and Veris's sale for $19.00 per share, with the firm seeking increased consideration and disclosures on behalf of shareholders.

prnewswire

XOMA Royalty

Veris Residential

Ligand Pharmac-B

XOMA Corp Pref Share 8.625 Perp 12/15/21

XOMA Pref Share XOMAO 8.375 Perp 04/15/22 B

17:25 ETAre XOMA, OGN, VRE Obtaining Fair Deals for their Shareholders?

RMAX

Class Action Attorney Juan Monteverde with Monteverde & Associates PC is investigating mergers involving Helix Energy Solutions Group (HLX), Organon & Co. (OGN), XOMA Royalty Corporation (XOMA), and RE/MAX Holdings, Inc. (RMAX). Helix shareholders will own 45% of the combined company post-merger, while Organon shareholders will receive $14.00 per share, XOMA shareholders $39.00 per share, and RE/MAX shareholders will receive either shares or $13.80 in cash. The firm has a successful track record in recovering funds for shareholders.

Helix Energy Solutions

RE/MAX

Real Brokerage

14:27 ETSHAREHOLDER ALERT: The M&A Class Action Firm Is Investigating The Merger--HLX, OGN, XOMA, and RMAX

Organon (OGN) has seen a significant share price surge, closing at $13.35, with a 47.6% return over the past year. Despite a 27.8% decline over three years, recent analysis suggests the stock is undervalued by 84.3% based on a Discounted Cash Flow (DCF) model, estimating an intrinsic value of $85.08 per share. Additionally, with a P/E ratio of 14.25x, below industry averages, Organon appears undervalued compared to peers. Investors are reassessing the company's potential amidst contrasting performance metrics.

Simplywall

Is It Time To Reassess Organon (OGN) After Its Sharp Recent Share Price Surge?

TBRG

CYCN

Halper Sadeh LLC is investigating Organon & Co. (NYSE: OGN), TruBridge, Inc. (NASDAQ: TBRG), and Cyclerion Therapeutics, Inc. (NASDAQ: CYCN) for potential violations of federal securities laws and breaches of fiduciary duties. The firm is concerned that insiders may benefit financially at the expense of ordinary shareholders. Shareholders are encouraged to contact the firm for legal rights and options regarding the proposed transactions, which may limit competing offers. Halper Sadeh LLC operates on a contingent fee basis, ensuring no upfront costs for clients.

Organon(OGN.US)

Organon & Co. (NYSE:OGN) Receives Average Rating of "Reduce" from Brokerages

Organon to Present New Research on Access and Value at ISPOR 2026 | OGN Stock News

17:25 ETAre XOMA, OGN, VRE Obtaining Fair Deals for their Shareholders?

14:27 ETSHAREHOLDER ALERT: The M&A Class Action Firm Is Investigating The Merger--HLX, OGN, XOMA, and RMAX

Is It Time To Reassess Organon (OGN) After Its Sharp Recent Share Price Surge?

14:55 ETAre OGN, TBRG, CYCN Obtaining Fair Deals for their Shareholders?

Organon | 10-Q: FY2026 Q1 Revenue Misses Estimate at USD 1.46 B